Niphon Chirapapaisan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Niphon Chirapapaisan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Akarawit Eiamsamarng
Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th
2 shared publications Manassawee Joradoln
Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Golden Jubilee Medical Center, Mahidol University, Bangkok, Thailand, mahidol.ac.th
2 shared publications- Chanon Ngamsombat
Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Jantima Tanboon
Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Jiruth Sriratanaban
Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
1 shared publication - Nasikarn Angkasekwinai
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
1 shared publication
Latest Publications
- Open Access
- 19 May 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2674358
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study
Patients with nontuberculous mycobacterial (NTM) diseases associated with anti-interferon gamma autoantibodies (anti-IFN-γ auto-Abs) often experience recurrences, despite prolonged treatment, which requires intravenous anti-mycobacterial therapy. Linezolid (LZD) shows a potential as an adjunct treatment, but there is limited data on its long-term efficacy and safety. We conducted a prospective study from December 2017 to April 2022, to evaluate the efficacy of a nine-month oral LZD regimen in reducing NTM treatment failure, defined as relapse and the need for intravenous anti-mycobacterial therapy for suspected uncontrolled NTM or death as well as to determine its tolerability. Among 40 adults (≥18 years) with NTM diseases and anti-IFN-γ auto-Abs treated with linezolid, 10 (25%) discontinued treatment early due to adverse events (AEs), including one death from suspected uncontrolled diseases at month seven. Of the 30 patients who completed the nine-month course, only five maintained their initial dose. The remaining 25 required dose modification: four temporarily paused treatment due to AEs, nine reduced to a half dose due to AEs, and 12 reduced their dose because of stable disease. By month nine, the cumulative incidence rates of relapse and treatment failure were 22.5 and 15.0%, respectively; consequently, 77.5% and 85.0% of patients remained free from the relapse and treatment failure. Overall, 24 patients (60%) reported a total of 31 AEs, with anemia and peripheral neuropathy being the most frequent. Our findings suggest that linezolid could be a valuable adjunct treatment for nontuberculous mycobacteria diseases in patients with anti-interferon gamma autoantibodies. However, close monitoring for adverse events is essential.
- 19 May 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2674358
Open AccessEfficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study
Patients with nontuberculous mycobacterial (NTM) diseases associated with anti-interferon gamma autoantibodies (anti-IFN-γ auto-Abs) often experience recurrences, despite prolonged treatment, which requires intravenous anti-mycobacterial therapy. Linezolid (LZD) shows a potential as an adjunct treatment, but there is limited data on its long-term efficacy and safety. We conducted a prospective study from December 2017 to April 2022, to evaluate the efficacy of a nine-month oral LZD regimen in reducing NTM treatment failure, defined as relapse and the need for intravenous anti-mycobacterial therapy for suspected uncontrolled NTM or death as well as to determine its tolerability. Among 40 adults (≥18 years) with NTM diseases and anti-IFN-γ auto-Abs treated with linezolid, 10 (25%) discontinued treatment early due to adverse events (AEs), including one death from suspected uncontrolled diseases at month seven. Of the 30 patients who completed the nine-month course, only five maintained their initial dose. The remaining 25 required dose modification: four temporarily paused treatment due to AEs, nine reduced to a half dose due to AEs, and 12 reduced their dose because of stable disease. By month nine, the cumulative incidence rates of relapse and treatment failure were 22.5 and 15.0%, respectively; consequently, 77.5% and 85.0% of patients remained free from the relapse and treatment failure. Overall, 24 patients (60%) reported a total of 31 AEs, with anemia and peripheral neuropathy being the most frequent. Our findings suggest that linezolid could be a valuable adjunct treatment for nontuberculous mycobacteria diseases in patients with anti-interferon gamma autoantibodies. However, close monitoring for adverse events is essential.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1) , 6652248
Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study
Purpose: The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods: This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG patients were reviewed and both acetylcholine receptor antibody (AChR Ab)‐positive and AChR Ab‐negative patients were included. Results: Seventy‐eight (39%) developed GMG, with a median conversion time of 16 months (IQR 7.88, 33.75) and a 2‐year conversion rate of 25.5%. AChR Ab positivity (adjusted HR 2.88, 95% CI 1.79–4.63), thymic abnormalities (adjusted HR 2.30, 95% CI 1.41–3.74), smoking (adjusted HR 1.78, 95% CI (1.04, 3.03), and pyridostigmine dosages > 180 mg/day (adjusted HR 2.33, 95% CI 1.41–3.87) were significantly associated with shorter conversion time. Conclusion: Thymic abnormalities and positive AChR Ab warrant routine assessment in all OMG patients. Smoking cessation is crucial, as it may impact conversion risk and time. Unlike previous findings suggesting a protective role of pyridostigmine, our data indicate a strong association between high‐dose pyridostigmine and conversion to GMG, likely reflecting underlying disease severity. This underscores the need for individualized risk assessment in OMG management.
- 1 January 2026
- Published by Wiley in Journal of Ophthalmology
- Vol. 2026 (1) , 6652248
Open AccessFactors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study
Purpose: The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods: This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG patients were reviewed and both acetylcholine receptor antibody (AChR Ab)‐positive and AChR Ab‐negative patients were included. Results: Seventy‐eight (39%) developed GMG, with a median conversion time of 16 months (IQR 7.88, 33.75) and a 2‐year conversion rate of 25.5%. AChR Ab positivity (adjusted HR 2.88, 95% CI 1.79–4.63), thymic abnormalities (adjusted HR 2.30, 95% CI 1.41–3.74), smoking (adjusted HR 1.78, 95% CI (1.04, 3.03), and pyridostigmine dosages > 180 mg/day (adjusted HR 2.33, 95% CI 1.41–3.87) were significantly associated with shorter conversion time. Conclusion: Thymic abnormalities and positive AChR Ab warrant routine assessment in all OMG patients. Smoking cessation is crucial, as it may impact conversion risk and time. Unlike previous findings suggesting a protective role of pyridostigmine, our data indicate a strong association between high‐dose pyridostigmine and conversion to GMG, likely reflecting underlying disease severity. This underscores the need for individualized risk assessment in OMG management.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 717-728
Budget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand
Objective: Severe blepharospasm is a disabling neurological condition that significantly affects patients’ quality of life. Botulinum toxin type A (BoNT-A) is considered the standard treatment due to its targeted therapeutic effect and fewer systemic side effects compared to oral medications. However, its high cost poses a barrier to access within Thailand’s healthcare system. This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Methods: A budget impact model was developed from the perspective of Thailand’s healthcare system over a 5-year time horizon. The current scenario (oral medications use) was compared with a new scenario involving BoNT-A treatment. The costs considered included drug acquisition, outpatient visits, and accident-related injuries. The base-case assumed gradual uptake of BoNT-A (30% in year 1, 50% in year 2, and 100% from year 3). Sensitivity analyses explored full uptake from year 1, no dose sharing, and inclusion of injury-related costs. Results: Excluding injury-related costs, the 5-year net budget impact (NBI) was 7.91 million THB (223,040 USD) for onabotulinumtoxin A and 7.27 million THB (205,064 USD) for abobotulinumtoxin A. Including injury-related costs reduced the NBI to 4.20 million THB (118,564 USD) and 3.57 million THB (100,588 USD), respectively. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. Conclusion: BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A’s inclusion in Thailand’s National List of Essential Medicine.
- 1 October 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 717-728
Open AccessBudget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand
Objective: Severe blepharospasm is a disabling neurological condition that significantly affects patients’ quality of life. Botulinum toxin type A (BoNT-A) is considered the standard treatment due to its targeted therapeutic effect and fewer systemic side effects compared to oral medications. However, its high cost poses a barrier to access within Thailand’s healthcare system. This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Methods: A budget impact model was developed from the perspective of Thailand’s healthcare system over a 5-year time horizon. The current scenario (oral medications use) was compared with a new scenario involving BoNT-A treatment. The costs considered included drug acquisition, outpatient visits, and accident-related injuries. The base-case assumed gradual uptake of BoNT-A (30% in year 1, 50% in year 2, and 100% from year 3). Sensitivity analyses explored full uptake from year 1, no dose sharing, and inclusion of injury-related costs. Results: Excluding injury-related costs, the 5-year net budget impact (NBI) was 7.91 million THB (223,040 USD) for onabotulinumtoxin A and 7.27 million THB (205,064 USD) for abobotulinumtoxin A. Including injury-related costs reduced the NBI to 4.20 million THB (118,564 USD) and 3.57 million THB (100,588 USD), respectively. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. Conclusion: BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A’s inclusion in Thailand’s National List of Essential Medicine.
- Open Access
- 25 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2537921
Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial
To evaluate the necessity of botulinum toxin A (BoNT-A) administration in the lower face of patients with hemifacial spasm (HFS). A randomized controlled non-inferiority crossover trial was conducted with 46 HFS patients (non-inferiority margin = 1). Patients were randomized (1:1) to receive either isolated periocular BoNT-A injections followed by conventional injections (periocular and lower face area) or the reverse sequence, with a 16-week washout. Primary outcomes were visual analog scale (VAS) for periocular and lower face regions at 4 weeks post injection. Secondary outcomes included the Hemifacial Spasm Grading Scale (HSGS), Samsung Medical Center grading system (SMC), HFS questionnaire (HFS-30), and adverse events. Trial registration: TCTR20220916002. Data from 43 patients were analyzed. Isolated periocular injections demonstrated non-inferiority to conventional injections. Periocular VAS was 0.488 ± 0.140 (isolated injections) and 0.279 ± 0.085 (conventional) , mean difference 0.209 (95% CI: 0.064, 0.354, p<0.01). Lower face VAS was 0.878 ± 0.167 and 0.582 ± 0.113, mean difference 0.295 (95% CI: 0.039, 0.552, p<0.01). No significant differences were noted in HSGS, SMC, or HFS-30 scores. Minor adverse events were observed in both techniques, while mouth drooping occured only with conventional injections. Isolated periocular injections resulted in slightly poorer symptom relief but did not exceed the non-inferiority margin, providing comparable efficacy to conventional injections in controlling HFS while using a lower total toxin dose and minimizing adverse effects.
- 25 July 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2537921
Open AccessEfficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial
To evaluate the necessity of botulinum toxin A (BoNT-A) administration in the lower face of patients with hemifacial spasm (HFS). A randomized controlled non-inferiority crossover trial was conducted with 46 HFS patients (non-inferiority margin = 1). Patients were randomized (1:1) to receive either isolated periocular BoNT-A injections followed by conventional injections (periocular and lower face area) or the reverse sequence, with a 16-week washout. Primary outcomes were visual analog scale (VAS) for periocular and lower face regions at 4 weeks post injection. Secondary outcomes included the Hemifacial Spasm Grading Scale (HSGS), Samsung Medical Center grading system (SMC), HFS questionnaire (HFS-30), and adverse events. Trial registration: TCTR20220916002. Data from 43 patients were analyzed. Isolated periocular injections demonstrated non-inferiority to conventional injections. Periocular VAS was 0.488 ± 0.140 (isolated injections) and 0.279 ± 0.085 (conventional) , mean difference 0.209 (95% CI: 0.064, 0.354, p<0.01). Lower face VAS was 0.878 ± 0.167 and 0.582 ± 0.113, mean difference 0.295 (95% CI: 0.039, 0.552, p<0.01). No significant differences were noted in HSGS, SMC, or HFS-30 scores. Minor adverse events were observed in both techniques, while mouth drooping occured only with conventional injections. Isolated periocular injections resulted in slightly poorer symptom relief but did not exceed the non-inferiority margin, providing comparable efficacy to conventional injections in controlling HFS while using a lower total toxin dose and minimizing adverse effects.
- Open Access
- 1 September 2020
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 15 (03) , 750-752
A cavernous venous malformation of the orbit mimicking an idiopathic orbital inflammation
Orbital cavernous venous malformations (CVMs) are usually slow progressing. Multiple CVMs, bilateral orbital CVMs, and acute presentations are rare. We present a rare, bilateral, orbital CVM with acute painful visual loss in the left eye. The initial clinical presentation mimicked an idiopathic orbital inflammation. Orbital magnetic resonance imaging revealed its rare location at the left orbital apex. Finally, pathology confirmed the presence of an intralesional hemorrhage of a CVM.
- 1 September 2020
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 15 (03) , 750-752
Open AccessA cavernous venous malformation of the orbit mimicking an idiopathic orbital inflammation
Orbital cavernous venous malformations (CVMs) are usually slow progressing. Multiple CVMs, bilateral orbital CVMs, and acute presentations are rare. We present a rare, bilateral, orbital CVM with acute painful visual loss in the left eye. The initial clinical presentation mimicked an idiopathic orbital inflammation. Orbital magnetic resonance imaging revealed its rare location at the left orbital apex. Finally, pathology confirmed the presence of an intralesional hemorrhage of a CVM.